Many different, intersecting strategies are available for managing germ-cell cancers, particularly in early-stage disease. Which is ‘right’ remains a matter of debate, and requires balancing efficacy against late effects, bearing in mind the complexity of treatment strategies and the available expertise.
HuddartR.A., O'DohertyM.J., PadhaniA., RustinG.J., MeadG.M., JoffeJ.K., VaseyP., HarlandS.J., LogueJ., DaugaardG., HainS.F., KirkS.J., MacKewnJ.E., StenningS.P.; NCRI Testis Tumour Clinical Study Group. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22–the NCRI Testis Tumour Clinical Study Group. J Clin Oncol.2007; 25: 3090–5.
2.
OechsleK., HartmannM., BrennerW., VenzS., WeissbachL., FranziusC., KlieschS., MuellerS., KregeS., HeicappellR., BaresR., BokemeyerC., de WitM.; German Multicenter Positron Emission Tomography Study Group. Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.J Clin Oncol.200826: 5930–5.
3.
NicolaiN., MiceliR., ArtusiR., PivaL., PizzocaroG., SalvioniR.. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.J Urol.2004; 171: 172–6.
4.
AlbersP., SienerR., KregeS., SchmelzH.U., DieckmannK.P., HeidenreichA., KwasnyP., PechoelM., LehmannJ., KlieschS., KöhrmannK.U., FimmersR., WeissbachL., LoyV., WittekindC., HartmannM.; German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.J Clin Oncol.2008; 26: 2966–72. Epub 2008 May 5.
FossåS.D., HorwichA., RussellJ.M., RobertsJ.T., CullenM.H., HodsonN.J., JonesW.G., YosefH., DuchesneG.M., OwenJ.R., GroschE.J., ChetiyawardanaA.D., ReedN.S., WidmerB., StenningS.P.. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial.Medical Research Council Testicular Tumor Working Group. J Clin Oncol.1999; 17: 1146.
7.
JonesW.G., FossaS.D., MeadG.M., RobertsJ.T., SokalM., HorwichA., StenningS.P.. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).J Clin Oncol.2005; 23: 1200–8.
8.
OliverR.T., MasonM.D., MeadG.M., von der MaaseH., RustinG.J., JoffeJ.K., de WitR., AassN., GrahamJ.D., ColemanR., KirkS.J., StenningS.P.; MRC TE19 collaborators and the EORTC 30982 collaborators. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.Lancet.2005; 366: 293–300.
9.
KregeS., BeyerJ., SouchonR., AlbersP.. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.Eur Urol.2008; 53: 497–513. Epub 2007 Dec 26.
10.
NielsenM.E., LimaG., SchaefferE.M., PorterJ., CadedduJ.A., TuerkI., KavoussiL.R..: Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer.Urology.2007; 70: 1168–72.
11.
CresswellJ., ScheitlinW., GozenA., LenzE., TeberD., RassweilerJ.. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.BJU Int.2008; 102: 844–8.
12.
RassweilerJ.J., ScheitlinW., HeidenreichA., LagunaM.P., JanetschekG.. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.Eur Urol.2008; 54: 1004–15. Epub 2008 Aug 13. Review.
OechsleK., HartmannM., BrennerW., VenzS., WeissbachL., FranziusC., KlieschS., MuellerS., KregeS., HeicappellR., BaresR., BokemeyerC., de WitM.; German Multicenter Positron Emission Tomography Study Group. Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study groupJ Clin Oncol.2008; 26: 5930–5.
15.
HeidenreichA., ThüerD., PolyakovS.. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.Eur Urol.2008; 53: 260–72. Epub 2007 Oct 31.
16.
De GiorgiU., NicolaiN., TanaS., TavoliniI.M., PalazziS., BracardaS., TedeschiL., PalmieriG., FrassinetiL., Da PozzoL., PastorinoU., EmilianiE., MarangoloM., PizzocaroG., RostiG., SalvioniR.. Italian Germ cell cancer Group. IGG practice guidelines on germ cell tumor in adult male patients.Tumori.2008; 94: 96–109.
17.
KorkolaJ.E., HeckS., OlshenA.B., ReuterV.E., BoslG.J., HouldsworthJ., ChagantiR.S.. In vivo differentiation and genomic evolution in adult male germ cell tumors.Genes Chromosomes Cancer.2008; 47: 43–55.
18.
LorchA., OechsleK., BokemeyerC., BeyerJ.. Salvage treatment in germ cell tumors: high-dose chemotherapy and the impact of prognostic factors.Urologe A.2009; 48: 364–71.
19.
NicolaiN., NecchiA., GianniL.. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.BJU Int.2009; 104: 340–6.
van DijkM.R., SteyerbergE.W., HabbemaJ.D.. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis.Eur J Cancer.2006; 42: 820–6. Review.
22.
van den Belt-DuseboutA.W., de WitR., GietemaJ.A., HorenblasS.. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.J Clin Oncol.2007; 25: 4370–8.
23.
HuddartR.A., NormanA., ShahidiM., HorwichA., CowardD., NichollsJ., DearnaleyD.P.. Cardiovascular disease as a long-term complication of treatment for testicular cancer.J Clin Oncol.2003; 21: 1513–23.
24.
TravisL.B., FossåS.D., SchonfeldS.J.. Second cancers among 40, 576 testicular cancer patients: focus on long-term survivors.J Natl Cancer Inst.2005; 97: 1354–65.
